N/A N=60 Inhibition of Lipid Peroxidation During Cardiac Surgery
Cardiopulmonary Bypass Induced Lipid Peroxidation
Primary: Plasma Isofuran Concentrations — 61.5; 67.7; 72.1; 82.7 pg/mL — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=46 Cytokine Removal in Cardiopulmonary Bypass Patients
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
N/A N=336 Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
Ischemic Heart Disease · Coronary Artery Disease · Ischemic Reperfusion Injury
Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L
Phase 4 N=86 The RAS, Fibrinolysis and Cardiopulmonary Bypass
Coronary Artery Disease · Angiotensin Converting Enzyme · Angiotensin Receptor Blockers
Primary: Tissue-type Plasminogen Activator (t-PA) Antigen Response — 14.36; 14.05; 11.97; 27.65 ng/mL — p=0.28
N/A N=18 Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)
Complication of Extracorporeal Circulation · Renal Impairment
Primary: Renal Blood Flow (RBF) — 554; 524; 564; 558 ml per minute per 1.73 m2 body surface — p=0.638
Phase 2 N=16 Inhaled NO as an Anti-inflammatory and Anti-reperfusion Agent in Infants and Children Undergoing Cardiopulmonary Bypass
Congenital Heart Disease
Primary: Serum Inflammatory Mediators Post CPB — 3.8; 3.4; 90.9; 78.3 ng/mL — p=>0.05
N/A N=190 Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass
Congenital Heart Disease · Disorder of Fetus or Newborn
Primary: Number of Participants With a Clinically Derived Composite Morbidity-mortality Outcome — 27; 40 Participants
Phase 3 N=201 Risk of Oxygen During Cardiac Surgery Trial
Cardiac Surgery
Primary: Intraoperative Systemic Oxidative Damage — 69; 83 pg/ml
N/A N=24 Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass
Ischemia/Reperfusion Injury After Neonatal Cardiac Surgery · Inflammatory Reaction After Neonatal Cardiac Surgery
Primary: Change in Biochemical Markers of Ischemia/Reperfusion Injury and Oxidative Damage (Positive ~ Increase From Pre-op) — 0.46; 0.64; 11.52; 26.98 ng/ml — p=>0.05
Phase 3 N=40 Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation
Inflammation · Platelet Dysfunction
Primary: Change in Platelet Count — -221; -242 Count of platelets — p=0.55
Phase 3 N=115 Bradykinin Receptor Antagonism During Cardiopulmonary Bypass
Cardiopulmonary Bypass · Inflammation · Fibrinolysis
Primary: Allogenic Blood Product Transfusion Risk — 47.4; 56.8; 52.5; 36.8 percentage of participants — p=0.72
N/A N=164 Extracardiac Complications After Cardiac Surgery
Acute Lung Injury · Sepsis · Infections
Primary: Acute Lung Injury After Cardiac Surgery — 20 participants — p=<0.05
Phase 2 N=448 Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia
Coronary Artery Bypass Surgery
Primary: Post-op CK-MB Levels — 71.70; 92.66 IU/L — p=<0.05
N/A N=29 Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
Heart Disease
Primary: Pulmonary Vascular Resistance — 153.8; 213.0; 174.6; 123.5 dyne*second/centimeter˄5 — p=<0.05
N/A N=200 Cerebral Oximetry and Neurocognitive Functions in Cardiosurgical Patients
Coronary Artery Disease · Postoperative Cognitive Dysfunction · Neurological Impairment
Primary: Difference in Incidence of Cognitive Impairment Between Groups. Change Between Preoperative and Postoperative Cognitive Function Was Assessed by Performing Standardized…
N/A N=40 Effect of Prewarming on Microcirculatory Response
Coronary Artery Bypass Graft Triple Vessel
Primary: Recovery Slope — 2.8; 3.1 % / sec (recovery slope unit)
N/A N=72 Comparison of Total Oxidant and Total Antioxidant Capacities in Low-Flow and High-Flow General Anesthesia
Oxidative Stress · Anesthesia
Primary: Comparison of Total Antioxidant Status (TAS) Levels Between the Two Groups — 1.76; 1.82; 1.83; 1.92 mmol Eq / L
N/A N=14 Modified Perfusion for Neonatal Aortic Arch Reconstruction
Aortic Arch Hypoplasia or Atresia
Primary: Intestinal Fatty Acid Binding Protein and C-reactive Protein
Phase 2 N=56 Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
Coronary Artery Bypass Grafting · Cardiopulmonary Bypass · Reperfusion Injury
Primary: Left Ventricular Stroke Work Index (LVSWI) — 42; 43; 29; 28 g*m/m2
N/A N=77 Preoperative Corticosteroid Therapy in Neonates Undergoing Cardiopulmonary Bypass
Congenital Heart Disease · Disorder of Fetus or Newborn
Primary: Primary Endpoint: Number of Participants With Low Cardiac Output Syndrome (LCOS) or Death at 36 Hours From Admission to the Intensive Care Unit (ICU) After Surgery…
Phase 3 N=60 Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF
Coronary Artery Bypass · Cardiopulmonary Bypass · Coronary Artery Disease
Primary: Plasma Troponin I at Baseline — 0.42; 0.17 ng/mL — p=0.993
Phase 4 N=40 Fibrinolysis Before Cardiopulmonary Bypass?
Pathologic Fibrinolysis
Primary: Di-Dimer Increase Before Cardiopulmonary Bypass — 317; 266; 317; 291 ng/mL
N/A N=59 Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins
Hyperglycemia
Primary: Forearm Blood Flow — 6.48; 9.2; 7.32; 8.26 ml/100 ml tissue/min
Phase 3 N=2,203 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants
Phase 4 N=100 The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery
Oxidative Stress · Cognition Disorders
Primary: Numbers of Participants With Postoperative Cognitive Dysfunction (POCD) — 12; 8 Participants — p=0.289
N/A N=80 Nitroglycerin Infusion During Cardiac Surgery
Lactic Acidosis · Blood Glucose, High
Primary: Plasma Lactate Level, Before Incision — 1.1; 1.0 mmol/L — p=0.618
N/A N=40 Effect of Postop Steroids on Cardiovascular/Respiratory Function in Neonates Undergoing Cardiopulmonary Bypass
Heart Disease Congenital Complex
Primary: Incidence of Low Cardiac Output Syndrome (LCOS) — 57; 26 percentage of patients — p=0.049
N/A N=105 Anesthesia and Lymphocytes Apoptosis
Anesthesia
Primary: Lymphocyte Count — 0.55; 0.73; 0.73 cells/nanoliter
N/A N=177 Microparticles in Stored RBC as Potential Mediators of Transfusion Complications
Coronary Artery Bypass
Primary: In Hospital Mortality — 0; 4 participants — p=0.142
N/A N=29 Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period
Hypoplastic Left Heart Syndrome · Total Anomalous Pulmonary Venous Return · Truncus Arteriosus
Primary: Systemic Oxidative Stress Based on Thiobarbituric Acid Reactive Substances (TBARS) — 1.21; 1.93; 1.09; 1.77 Fold Change from Baseline — p=<0.01